Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer

Authors: Ning Li, Minghong Chen, Yansha Cao, Hua Li, Jinping Zhao, Zhenhua Zhai, Fu Ren, Keyan Li

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

CRC is one of the most common malignancies worldwide, and its molecular mechanisms remain unclear. Elevated levels of BAG3 have been reported in various tumors. The present study aimed to explore the expression and function of BAG3 in CRC.

Methods

BAG3 protein expression was evaluated in 90 CRC specimens using immunohistochemistry in tissue microarrays, and the correlation between BAG3 expression and the clinicopathological features were assessed. In HCT116 cells BAG3 overexpression cell models were constructed, and CRISPR/Cas9 was used for BAG3 knockout. Western blotting and quantitative real-time PCR were used to determine BAG3 expression in HCT-116 Cells. Cell proliferation, migration and invasion were analyzed by cell counting, colony formation assay, EdU cell proliferation assay, RTCA growth curve assays, wound-healing migration assay and transwell invasion assay. The influence of BAG3 expression level on chemoresistance in HCT-116 cells was examined. Gene expression microarray and IPA analyses were employed to explore signaling pathways associated with the control of BAG3.

Results

Using immunohistochemistry, this study found that BAG3 was markedly upregulated in colorectal cancer tissues and that BAG3 levels were significantly associated with tumor size and gender. BAG3 overexpression promoted HCT-116 cell growth, migration and invasion in vitro. In contrast, BAG3 knockout inhibited HCT-116 cell growth, migration and invasion. HCT-116 cells with high expression of BAG3 had higher cell viability and lower apoptosis rate than control cells after treatment with 5-FU, while the BAG3 knockout group demonstrated the opposite effects. So BAG3 expression level was associated with chemoresistance to 5-FU in HCT-116 cells. Gene expression microarrays and bioinformatics analyses of HCT-116 cells with BAG3 knockout demonstrated the involvement of BAG3 in signaling pathways associated with the control of cell proliferation, migration, invasion and chemoresistance in CRC.

Conclusions

In conclusion, this study provided evidence that BAG3 has a relevant role in CRC biology, and defined potential molecular pathways and networks. So BAG3 may be considered as a potential therapeutic target for anti-tumor therapy in colorectal cancer.
Literature
1.
2.
3.
Tarraga Lopez PJ, Albero JS, Rodriguez-Montes JA. Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol. 2014;7:33–46.PubMedPubMedCentral
4.
Ni Y, Xie G, Jia W. Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014;13(9):3857–70.CrossRefPubMed
5.
Romano MF, et al. BAG3 protein controls B-chronic lymphocytic leukaemia cell apoptosis. Cell Death Differ. 2003;10(3):383–5.CrossRefPubMed
6.
Du ZX, et al. Proteasome inhibitor MG132 induces BAG3 expression through activation of heat shock factor 1. J Cell Physiol. 2009;218(3):631–7.CrossRefPubMed
7.
Chiappetta G, et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab. 2007;92(3):1159–63.CrossRefPubMed
8.
Hishiya A, Kitazawa T, Takayama S. BAG3 and Hsc70 interact with actin capping protein CapZ to maintain myofibrillar integrity under mechanical stress. Circ Res. 2010;107(10):1220–31.CrossRefPubMedPubMedCentral
9.
Liao Q, et al. The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett. 2001;503(2–3):151–7.CrossRefPubMed
10.
Bonelli P, et al. BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia. 2004;18(2):358–60.CrossRefPubMed
11.
Wang HQ, et al. Involvement of JNK and NF-kappaB pathways in lipopolysaccharide (LPS)-induced BAG3 expression in human monocytic cells. Exp Cell Res. 2012;318(1):16–24.CrossRefPubMed
12.
Wang HQ, et al. Transcriptional upregulation of BAG3 upon proteasome inhibition. Biochem Biophys Res Commun. 2008;365(2):381–5.CrossRefPubMed
13.
Takayama S, Xie Z, Reed JC. An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem. 1999;274(2):781–6.CrossRefPubMed
14.
15.
Yunoki T, et al. BAG3 protects against hyperthermic stress by modulating NF-kappaB and ERK activities in human retinoblastoma cells. Graefes Arch Clin Exp Ophthalmol. 2015;253(3):399–407.CrossRefPubMed
16.
17.
Chiappetta G, et al. BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein. J Clin Endocrinol Metab. 2012;97(1):E115–20.CrossRefPubMed
18.
Kuma A, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004;432(7020):1032–6.CrossRefPubMed
19.
Rosati A, et al. Apoptosis inhibition in cancer cells: a novel molecular pathway that involves BAG3 protein. Int J Biochem Cell Biol. 2007;39(7–8):1337–42.CrossRefPubMed
20.
Carra S, Seguin SJ, Landry J. HspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagy. Autophagy. 2008;4(2):237–9.CrossRefPubMed
21.
Du ZX, et al. Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells. Biochem Biophys Res Commun. 2008;369(3):894–8.CrossRefPubMed
22.
Zhu H, Liu P, Li J. BAG3: a new therapeutic target of human cancers? Histol Histopathol. 2012;27(3):257–61.PubMed
23.
24.
25.
Medrano G, et al. Comprehensive selection of reference genes for quantitative RT-PCR analysis of murine extramedullary hematopoiesis during development. PLoS One. 2017;12(7):e0181881.CrossRefPubMedPubMedCentral
26.
Li Y, et al. CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF. Tumour Biol. 2015;36(2):737–45.CrossRefPubMed
27.
Tummala S, et al. 5-fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer. Drug Deliv. 2016;23(8):2902–10.CrossRefPubMed
28.
McCollum AK, Casagrande G, Kohn EC. Caught in the middle: the role of Bag3 in disease. Biochem J. 2009;425(1):e1–3.CrossRefPubMed
29.
30.
Gandhi PU, et al. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. Clin Chim Acta. 2015;445:73–8.CrossRefPubMed
31.
32.
Takayama S, Reed JC. Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol. 2001;3(10):E237–41.CrossRefPubMed
33.
Li M, et al. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther. 2014;7:1653–61.PubMedPubMedCentral
34.
Doong H, Vrailas A, Kohn EC. What's in the 'BAG'?--a functional domain analysis of the BAG-family proteins. Cancer Lett. 2002;188(1–2):25–32.CrossRefPubMed
35.
36.
Rosati A, et al. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Am J Pathol. 2012;181(5):1524–9.CrossRefPubMed
37.
Pagliuca MG, et al. Regulation by heavy metals and temperature of the human BAG-3 gene, a modulator of Hsp70 activity. FEBS Lett. 2003;541(1–3):11–5.CrossRefPubMed
38.
39.
Fuchs M, et al. Identification of the key structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem J. 2009;425(1):245–55.CrossRefPubMed
40.
41.
Shi H, et al. BAG3 regulates cell proliferation, migration, and invasion in human colorectal cancer. Tumour Biol. 2016;37(4):5591–7.CrossRefPubMed
42.
Yang X, et al. Bag-3 expression is involved in pathogenesis and progression of colorectal carcinomas. Histol Histopathol. 2013;28(9):1147–56.PubMed
43.
De Marco M, et al. Role of BAG3 in cancer progression: a therapeutic opportunity. Semin Cell Dev Biol. 2018,78:85–92.
44.
Brendel A, et al. Differential regulation of apoptosis-associated genes by estrogen receptor alpha in human neuroblastoma cells. Restor Neurol Neurosci. 2013;31(2):199–211.PubMed
45.
Qiu S, et al. Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy. Oncol Rep. 2017;38(1):309–16.CrossRefPubMed
Metadata
Title
Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer
Authors
Ning Li
Minghong Chen
Yansha Cao
Hua Li
Jinping Zhao
Zhenhua Zhai
Fu Ren
Keyan Li
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4657-2

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients

Research article

Identification of methylation sites and signature genes with prognostic value for luminal breast cancer

Research article

Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer

Research article

Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma

Research article

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Case report

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits